Valuation: Cutia Therapeutics

Market Cap 213M 250M 31.89M 28.6M 26.14M 23.86M 44.96M 3B 46.37M 315M 126M 1.6B 120M 117M 5.05B P/E 2026 *
19x
P/E 2027 * 4.08x
Enterprise Value 213M 250M 31.89M 28.6M 26.14M 23.86M 44.96M 3B 46.37M 315M 126M 1.6B 120M 117M 5.05B EV / Sales 2026 *
0.36x
EV / Sales 2027 * 0.22x
Free-Float
33.82%
Yield 2026 *
-
Yield 2027 * -
1 day-5.63%
1 week-2.90%
Current month-2.90%
1 month-23.43%
3 months-73.52%
6 months-85.43%
Current year-85.24%
1 week 0.64
Extreme 0.645
0.74
1 month 0.6
Extreme 0.6
0.9
Current year 0.6
Extreme 0.6
5.51
1 year 0.6
Extreme 0.6
7.27
3 years 0.6
Extreme 0.6
24
5 years 0.6
Extreme 0.6
32.6
10 years 0.6
Extreme 0.6
32.6
Manager TitleAgeSince
Chief Executive Officer 48 01/09/2019
Chief Tech/Sci/R&D Officer 54 09/09/2019
Corporate Secretary 45 28/08/2025
Director TitleAgeSince
Director/Board Member 48 12/05/2020
Chairman 63 23/08/2019
Director/Board Member 45 23/08/2019
Date Insider Type Main position Quantity % Market Cap. Importance
5/10/26 Other

Founder

-81,400 0.0217%
30/9/26 Other

Chief Financial Officer

-210,847 0.0563%
28/9/26 Other

Founder

-1,302,800 0.3478%
Change 5-day change 1-year change 3-year change Capi.($)
-5.63%-2.90%-89.48%-96.82% 31.89M
-0.79%-4.48%+44.44%+127.49% 1,206B
+1.43%+1.11%+47.73%+82.08% 665B
+1.07%-1.21%+32.99%+106.31% 515B
-0.36%-3.25%+47.17%+64.58% 381B
-0.14%-1.87%+71.05%+40.63% 362B
-0.78%-0.52%+30.57%+57.98% 307B
-0.80%-0.21%+8.54%+35.56% 289B
+0.03%-1.20%+45.89%+68.76% 249B
-0.41%-2.22%+35.24%+105.68% 207B
Average -0.64%-1.68%+27.42%+59.22% 417.98B
Weighted average by Cap. -0.04%-1.96%+42.24%+88.38%

Financials

2026 *2027 *
Net sales 588M 690M 88.05M 78.97M 72.17M 65.88M 124M 8.28B 128M 870M 347M 4.42B 330M 323M 13.94B 961M 1.13B 144M 129M 118M 108M 203M 13.53B 209M 1.42B 567M 7.22B 540M 529M 22.79B
Net income 10M 11.74M 1.5M 1.34M 1.23M 1.12M 2.11M 141M 2.18M 14.79M 5.9M 75.11M 5.62M 5.5M 237M 50M 58.7M 7.49M 6.72M 6.14M 5.6M 10.55M 704M 10.89M 73.97M 29.5M 376M 28.1M 27.5M 1.19B
Net Debt - -
Projected Income Statement - Annual - Cutia Therapeutics
Logo Cutia Therapeutics
Cutia Therapeutics is an investment holding company principally engaged in the dermatology biopharmaceutical business. The Company is dedicated to developing solutions in the dermatology treatment and care market, including scalp diseases and care, skin diseases and care, topical anesthesia and localized adipose accumulation management. The Company is primarily engaged in the distribution of scalp diseases and care products, as well as certain skin care products. The Company's principal pipeline products include topical finasteride spray CU-40102, topical 4% minocycline foam CU-10201, topical novel small molecule agent CU-10101, localized topical lidocaine and tetracaine cream CU-30101 and recombinant mutant collagenase CU-20401.
Employees
268
Date Price Change Volume
06/11/26 HKD 0.6700 -5.63% 118,400
05/11/26 HKD 0.7100 +2.90% 3,000
04/11/26 HKD 0.6900 -0.72% 66,400
03/11/26 HKD 0.6950 +2.21% 119,800
02/11/26 HKD 0.6800 -1.45% 87,800
Trader
-
Investor
Global
-
Quality
ESG MSCI
-
MarketScreener Ratings - Cutia Therapeutics
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.5707CNY
Average target price
6.572CNY
Spread / Average Target
+1,051.58%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Cutia Therapeutics
  1. Stock Market
  2. Stocks
  3. 2487 Stock